share_log

Asensus Surgical (NYSEAMERICAN:ASXC) Receives New Coverage From Analysts at Cantor Fitzgerald

Defense World ·  Sep 9, 2022 04:42

Cantor Fitzgerald started coverage on shares of Asensus Surgical (NYSEAMERICAN:ASXC – Get Rating) in a report issued on Thursday morning, The Fly reports. The brokerage issued an overweight rating and a $1.50 target price on the stock.

Separately, HC Wainwright decreased their target price on shares of Asensus Surgical from $4.00 to $3.00 in a research note on Wednesday, August 10th.

Get Asensus Surgical alerts:

Asensus Surgical Stock Performance

ASXC stock opened at $0.54 on Thursday. Asensus Surgical has a one year low of $0.35 and a one year high of $2.31.

Asensus Surgical (NYSEAMERICAN:ASXC – Get Rating) last issued its earnings results on Monday, August 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $0.99 million during the quarter, compared to analysts' expectations of $1.25 million.

Institutional Trading of Asensus Surgical

Hedge funds have recently modified their holdings of the business. Millennium Management LLC boosted its stake in Asensus Surgical by 3,552.4% in the 2nd quarter. Millennium Management LLC now owns 5,040,838 shares of the company's stock worth $2,007,000 after purchasing an additional 4,902,823 shares in the last quarter. Walker Asset Management LLC bought a new position in Asensus Surgical during the 2nd quarter valued at about $138,000. Advisor Group Holdings Inc. lifted its stake in Asensus Surgical by 12.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 279,923 shares of the company's stock valued at $2,090,000 after acquiring an additional 30,676 shares during the period. AQR Capital Management LLC bought a new position in Asensus Surgical during the 2nd quarter valued at about $106,000. Finally, GSA Capital Partners LLP bought a new position in Asensus Surgical during the 1st quarter valued at about $138,000.

About Asensus Surgical

(Get Rating)

Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.

Featured Articles

  • Get a free copy of the StockNews.com research report on Asensus Surgical (ASXC)
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
  • Are These Green Energy Companies Right For Your Portfolio?
  • When Will the Hangover Finally Be Over for Seagate Technology?
  • Does Enphase Energy Have the Juice to Keep Powering Higher?
  • The One Hydrogen Fuel Cell Stock To Rule Them All

Receive News & Ratings for Asensus Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asensus Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment